BioNexus Gene Lab announces the signing of a strategic partnership Memorandum of Understanding or MOU, with Shenzhen Rongguang Health Group, a major healthcare services provider in China. This partnership aims to expand the Company’s expertise and presence in cancer screening, precision medicine, and preventative healthcare through its subsidiary MRNA Scientific Sdn Bhd.The partnership between the Company and Shenzhen Rongguang Health Group represents a significant step forward in developing advanced healthcare technologies, with a focus on early cancer detection, personalized healthcare solutions, and broader preventative care. By combining the strengths of the Company’s proprietary molecular diagnostics and Shenzhen Rongguang Health Group’s healthcare infrastructure, the collaboration will drive innovations in early detection, regenerative medicine, and chronic disease management.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGLC:
- BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
- Bionexus Gene Lab’s Chemrex invests RM 2M to begin color paste production
- BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production
- BioNexus Receives Government Backing for Healthcare Tech
- BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd